Details of the Drug
General Information of Drug (ID: DME4856)
Drug Name |
2-amino-quinoline-3-carboxylic acid amide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2-aminoquinoline-3-carboxamide; 31407-28-0; 3-Quinolinecarboxamide, 2-amino-; 2-amino-quinoline-3-carboxylic acid amide; 2-amino-3-quinolinecarboxamide; CHEMBL206956; GXZOXGRLLFZVGF-UHFFFAOYSA-N; ZERO/004541; AC1NP94V; SCHEMBL30837; CTK7D2638; MolPort-002-742-881; ZX-AN021879; ALBB-023365; STK735522; BDBM50186621; SBB012747; ZINC19890815; FCH854771; AKOS003368785; MCULE-6676169786; NCGC00340196-01; 2-Aminoquinoline-3-carboxylic acid amide; OR346178; KB-118564; 2-amino-3-quinolinecarboxamide, AldrichCPR; ST4128359; R9463
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 187.2 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||